Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant milestone for Dechra Pharmaceuticals-B (德琪医药-B), enhancing its market presence and competitiveness in the biopharmaceutical sector [1]. Company Summary - Dechra Pharmaceuticals-B's stock rose nearly 6%, with a current price of 4.34 HKD and a trading volume of 9.4944 million HKD [1]. - The approved indications for Selinexor include treatment for multiple myeloma in combination with Bortezomib and Dexamethasone for adult patients who have received at least one prior therapy, and for relapsed or refractory diffuse large B-cell lymphoma as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not candidates for hematopoietic stem cell transplantation [1]. Industry Summary - The approval signifies Dechra Pharmaceuticals-B's ongoing enhancement in research and market promotion capabilities within the biopharmaceutical field [1]. - The introduction of Selinexor is expected to address the treatment needs for relevant diseases in the Hong Kong market, thereby improving the company's competitiveness in the biotechnology industry [1].

Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant milestone for Dechra Pharmaceuticals-B (德琪医药-B), enhancing its market presence and competitiveness in the biopharmaceutical sector [1] Group 1: Company Developments - Dechra Pharmaceuticals-B's stock rose nearly 6%, with a current price of 4.34 HKD and a trading volume of 9.4944 million HKD [1] - The approved applications are for the treatment of multiple myeloma (in combination with Bortezomib and Dexamethasone for adult patients who have received at least one prior therapy) and relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not candidates for hematopoietic stem cell transplantation) [1] Group 2: Market Implications - The approvals signify Dechra Pharmaceuticals-B's further expansion in the Hong Kong market, which is crucial for the company's business development [1] - The launch of Selinexor is expected to meet the treatment needs for relevant diseases in the Hong Kong market, thereby enhancing the company's competitiveness in the biotechnology industry [1]

Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant expansion for the company in the Hong Kong market, enhancing its competitiveness in the biopharmaceutical industry [1] Group 1: Company Developments - The stock price of Dechra Pharmaceuticals-B (德琪医药-B) increased by approximately 6%, reaching HKD 4.34, with a trading volume of HKD 9.4944 million [1] - The approved applications are for the treatment of multiple myeloma (in combination with bortezomib and dexamethasone for adult patients who have received at least one prior therapy) and relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not eligible for hematopoietic stem cell transplantation) [1] Group 2: Industry Implications - The approval signifies the company's ongoing enhancement in research and market promotion capabilities within the biopharmaceutical sector [1] - The introduction of Selinexor is expected to meet the treatment needs for relevant diseases in the Hong Kong market, thereby improving the company's competitive position in the biotechnology industry [1]

Core Viewpoint - The Hong Kong government has approved two supplemental new drug applications (sNDA) for the drug Selinexor (希维奥) by the company, allowing its use in treating multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma [1] Group 1: Drug Approvals - The approval includes the use of Selinexor in combination with Bortezomib and Dexamethasone (XVd) for adult patients with multiple myeloma who have received at least one prior therapy [1] - Selinexor is also approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL), specifically for those who have undergone at least two lines of systemic therapy and are not eligible for hematopoietic stem cell transplantation due to follicular lymphoma [1]

Core Viewpoint - The Hong Kong Special Administrative Region Government's Department of Health has approved two supplemental new drug applications (sNDA) for the drug Xivio (Selinexor) [1] Group 1: Drug Approvals - Xivio is approved for use in combination with Bortezomib and Dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy [1] - Xivio is also approved as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL), specifically for those who have received at least two lines of systemic therapy and are not candidates for hematopoietic stem cell transplantation due to follicular lymphoma [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Antengene Corporation Limited 1 關於德琪醫藥 德琪醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6996） 自願公告 ATG-022聯合KEYTRUDA® （帕博利珠單抗）±化療的IB/II期研究 於中國獲授予IND批准 本公告由德琪醫藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願作 出，以知會本公司股東及潛在投資者有關本集團之最新業務發展。本公司董事會 （「董事會」）欣然宣佈，中國國家藥品監督管理局（國家藥監局）已批准用於評估 ATG-022（CLDN18.2抗體藥物偶聯物ADC）聯合MSD (Merck & Co., Inc., Rahway, NJ, USA)的抗PD 1療法KEYTRUDA® （帕博利珠單抗）以及ATG-022聯合帕博利 珠單抗及化療的Ib/II期CLINCH-2研究的研究性新藥(IND)申請。 承董事會命 德琪醫藥有限公 ...

Group 1: Baby and Childcare Sector - The baby and childcare concept stocks mostly opened higher, with notable increases in shares of companies such as Jinxin Reproductive Medicine (1951.HK) up 8.93%, H&H International Holdings (1112.HK) up 7.33%, and China Feihe (6186.HK) up 5.12% following the announcement of a new childcare subsidy policy [1] - The new policy, effective from January 1, 2025, provides an annual subsidy of 3,600 yuan for each child until they reach three years old, which is expected to boost the sector [1] Group 2: Pharmaceutical Sector - WuXi AppTec (2359.HK) opened over 4% higher after reporting a revenue of 20.799 billion yuan for the six months ending June 30, 2025, a year-on-year increase of 20.6%, with a net profit of 8.287 billion yuan, up 95.5% [1] - Fosun Pharma (2196.HK) saw a 1.37% increase after signing a licensing agreement for AR1001, aimed at treating Alzheimer's disease and other neurological disorders [2] - Deqi Pharmaceutical (6996.HK) rose 4.70% after receiving approval for a new indication of its drug, Xivio, for treating multiple myeloma [2] - Kangzheng Pharmaceutical (0867.HK) increased over 2% after announcing the acceptance of its new drug application for ZUNVEYL, aimed at treating Alzheimer's symptoms [4] - BeiGene (6160.HK) rose over 3% following a positive recommendation from the European Medicines Agency for its drug, Tislelizumab, for non-small cell lung cancer [4] Group 3: Automotive Sector - Hong Kong automotive dealer stocks rose, with Zhongsheng Holdings (0881.HK) up nearly 6% and Yongda Automotive (3669.HK) up over 4%, driven by expectations of improved profit margins from new car sales due to government policies [2] - UBS reported that Zhongsheng and Yongda's stock prices rebounded approximately 20% and 5% respectively, as the market anticipates industry consolidation and improved profitability [2] Group 4: Beverage Sector - Hong Kong Brewery (0236.HK) surged 26% after reporting a revenue of approximately 390 million HKD for the first half of 2025, a year-on-year increase of 3.22%, with a net profit of 49.644 million HKD, up 31.97% [3] Group 5: Securities Sector - Chinese brokerage stocks collectively declined, with Shenwan Hongyuan (6806.HK) down nearly 5%, amid tightening regulatory scrutiny in the securities industry, which has seen over 30 fines issued recently [3]